Browse articles from EyeWorld.org related to ASCRS. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves nasal spray for dry eye ➤ Survey: 70% of adults don’t plan on receiving an eye exam this year ➤ Positive results in Phase 3 study for Acanthamoeba keratitis treatment ➤ Research on first-in-class therapy for retinal degenerative disease ➤ ASCRS news and events
➤ Phase 3 clinical trial results for once-daily netarsudil ophthalmic solution ➤ Dexamethasone ophthalmic insert approved for new indication ➤ Results from home OCT feasibility study ➤ FDA accepts application for brolucizumab for DME ➤ Companies form alliance to develop nomograms, lens constants and astigmatism calculations ➤ AAO announces next CEO ➤ ASCRS news and events
➤ Positive topline results from Phase 3 trial for first-in-class dry eye drop ➤ Study: Long-term efficacy of neuromyelitis optica spectrum disorder treatment ➤ Long-term data from gene therapy injection for wet AMD ➤ Positive data from Phase 1/2 trial of gene therapy for geographic atrophy ➤ Ophthalmic device company partners with augmented reality tech company
➤ Survey: Patient perspectives on presbyopia ➤ Study: Wearable visual field testing device correlates with standard testing, offers efficiency ➤ Endpoints not met in blepharitis drug trial ➤ Retinal cell protection observed in non-clinical model with investigational IOP-lowering drug ➤ Extension study of investigational wet AMD therapy shows reduction of injection burden ➤ 12-month safety data reported from Phase 3 bevacizumab trial ➤ ASCRS news and events
➤ New and updated products for cataract workflow announced ➤ FDA approves first biosimilar in ophthalmology ➤ Acquisition of gene therapy company ➤ Licensing agreement for compounds targeting Demodex mites ➤ ASCRS news and events
➤ Patient enrollment complete for Phase 2 trial of DED drug candidate ➤ New investigational drug candidates for cornea, glaucoma, and wet AMD ➤ IND filed for glaucoma drug candidate ➤ Collaboration for one-time treatment of several retinal conditions ➤ ASCRS news and events
➤ Phase 4 trial for thyroid eye disease begins ➤ Glaukos submits supplemental pre-market approval application for iStent infinite ➤ Gene therapy for Leber hereditary optic neuropathy receives milestone designation in U.K. ➤ ASCRS news and events
➤ Phase 2 results for cream to treat signs, symptoms of dry eye associated with MGD ➤ Studies support clinical value of ultra-widefield and SS-OCT imaging device ➤ New combination treatment shows promise for metastatic uveal melanoma ➤ ASCRS news and events
➤ Study: Standalone trabeculotomy/viscodilation 24-month outcomes ➤ Proof of concept for dropless immunosuppression after PK ➤ Topline Phase 2 data for high-dose aflibercept in wet AMD ➤ Companies enter licensing agreement for investigational ophthalmic therapies ➤ ASCRS news and events
➤ Phase 3 clinical trials compare brolucizumab to aflibercept for DME ➤ Study: Randomized clinical trial evaluates combination drops, drop monotherapy, and dropless cataract surgery ➤ Commercial rights agreement for triamcinolone drug candidate ➤ ASCRS news and events